diabetestalk.net

Januvia Tradjenta Conversion

Dpp-4 Inhibitors - Dipeptidyl Peptidase-4 Inhibitor - Gliptins

Dpp-4 Inhibitors - Dipeptidyl Peptidase-4 Inhibitor - Gliptins

The authors make no claims of the accuracy of the information contained herein; and these suggested doses and/or guidelines are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this document shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material. PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER. Products alogliptin -NESINA® Linagliptin - Tradjenta™ Saxagliptin - Onglyza™ Sitagliptin - Januvia® Combination Products JANUMET® (sitagliptin and metformin HCl) tablets JANUMET ® XR (sitagliptin and metformin HCl extended-release) JENTADUETO® XR (linagliptin and metformin hydrochloride ER) KOMBIGLYZE XR (saxagliptin and metformin HCl ER) OSENI® (alogliptin and pioglitazone) --® Typical reductions in A1C values - DPP-4 INHIBITORS: ~ 0.74% (0.73 - 1.2) Background Overview Secretagogues Insulin sensitizers Alpha-glucosidase inh Peptide analogs INDICATIONS AND USAGE NESINA is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitation of Use: Not for treatment of type 1 diabetes or diabetic ketoacidosis. DOSAGE AND ADMINISTRATION •The recommended dose in patients with normal renal function or mild renal impairment is 25 mg once daily. •Can be taken with or without food. •Adjust dose if moderate or severe renal impairment or end-stage renal disease (ESRD). DOSAGE FORMS AND STRENGTHS Tablets: 25 mg, 12.5 mg and 6.25 mg CONTRAINDICATIONS History of a serious hypersensitiv Continue reading >>

Januvia : Januvia Tradjenta Conversion, Januvia And Alcohol, Januvia 50 Mg Price In Pakistan

Januvia : Januvia Tradjenta Conversion, Januvia And Alcohol, Januvia 50 Mg Price In Pakistan

Januvia tradjenta conversion januvia einnahme [23] The clearance by the kidneys is lower, januvia contraindications as kidney function has not fully developed. De Diego-Sastre JI, Prim-Espada MP, Fernandez-Garcia F. It is now used mainly topically because of renal toxicity and ototoxicity (to hearing). Tanto idosos quanto pacientes com insuficincia renal 41 possuem um risco aumentado de desenvolver efeitos adversos neurolgicos e devem ser monitorados com cautela para a monitorao destes efeitos. People who have hydrocephalus usually need a shunt system for the rest of their lives, and regular monitoring is required. This was not a very sturdy arrangement, prevacid fdt leaflet januvia vs tradjenta as one woman found out the hard way in 1820: "They are the ugliest things I ever saw: I will never put them on again. Interestingly, the modern trend of women living longer than men is reflected in the historic record once the issue of childbirth is factored out; in other words, the same gender advantage that we see in life expectancy trends now was shared by past generations of women once they reached the end of their childbearing years. The NOS criteria specify that community controls are preferable to hospital controls but it could be argued that in studies where women with PCOS were recruited from hospitals and clinics, a hospital or clinic control group may be the most appropriate comparison provided that the controls had medical conditions of comparable impact to PCOS. It has helped focus the mind, januvia tradjenta conversion as has a strong mutual dislike of each other, which was fuelled in part by being attracted to the same man, ATP Tour heart throb Grigor Dimitrov. FREE, this month only, Los Angeles, Seattle, Dallas, San Francisco, Vancouver, Toronto & Oslo. The cour Continue reading >>

Comparison Of Vildagliptin Twice Daily Vs. Sitagliptin Once Daily Using Continuous Glucose Monitoring (cgm): Crossover Pilot Study (j-victoria Study)

Comparison Of Vildagliptin Twice Daily Vs. Sitagliptin Once Daily Using Continuous Glucose Monitoring (cgm): Crossover Pilot Study (j-victoria Study)

Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): Crossover pilot study (J-VICTORIA study) Sakamoto et al.; licensee BioMed Central Ltd.2012 No previous studies have compared the DPP-4 inhibitors vildagliptin and sitagliptin in terms of blood glucose levels using continuous glucose monitoring (CGM) and cardiovascular parameters. Twenty patients with type 2 diabetes mellitus were randomly allocated to groups who received vildagliptin then sitagliptin, or vice versa. Patients were hospitalized at 1 month after starting each drug, and CGM was used to determine: 1) mean ( standard deviation) 24-hour blood glucose level, 2) mean amplitude of glycemic excursions (MAGE), 3) fasting blood glucose level, 4) highest postprandial blood glucose level and time, 5) increase in blood glucose level after each meal, 6) area under the curve (AUC) for blood glucose level 180 mg/dL within 3 hours after each meal, and 7) area over the curve (AOC) for daily blood glucose level <70 mg/dL. Plasma glycosylated hemoglobin (HbA1c), glycoalbumin (GA), 1,5-anhydroglucitol (1,5AG), immunoreactive insulin (IRI), C-peptide immunoreactivity (CPR), brain natriuretic peptide (BNP), and plasminogen activator inhibitor-1 (PAI-1) levels, and urinary CPR levels, were measured. The mean 24-hour blood glucose level was significantly lower in patients taking vildagliptin than sitagliptin (142.1 35.5 vs. 153.2 37.0 mg/dL; p = 0.012). In patients taking vildagliptin, MAGE was significantly lower (110.5 33.5 vs. 129.4 45.1 mg/dL; p = 0.040), the highest blood glucose level after supper was significantly lower (206.1 40.2 vs. 223.2 43.5 mg/dL; p = 0.015), the AUC (180 mg/dL) within 3 h was significantly lower after breakfast (484.3 vs. 897.9 mg/min/dL; p = Continue reading >>

Translate A1c Into Glucose Levels

Translate A1c Into Glucose Levels

TRADJENTA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. TRADJENTA should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. TRADJENTA has not been studied in patients with a history of pancreatitis, and it is unknown if using TRADJENTA increases the risk of developing pancreatitis in these patients. TRADJENTA is contraindicated in patients with a history of hypersensitivity reaction to linagliptin, such as anaphylaxis, angioedema, exfoliative skin conditions, urticaria, or bronchial hyperreactivity. Acute pancreatitis, including fatal pancreatitis, has been reported in patients taking TRADJENTA. Take careful notice of potential signs and symptoms of pancreatitis and, if suspected, promptly discontinue and initiate appropriate management. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using TRADJENTA. Heart failure has been observed with two other members of the dipeptidyl peptidase-4 (DPP-4) inhibitor class. Consider the risks and benefits of TRADJENTA in patients at risk for heart failure, such as those with a prior history of heart failure and a history of renal impairment. Monitor patients for signs and symptoms. Advise patients of the symptoms of heart failure and to immediately report such symptoms. If heart failure develops consider discontinuation of TRADJENTA. The use in combination with insulin or insulin secretagogues (e.g., sulfonylurea) increases the risk of hypoglycemia. A lower dose of insulin or insulin secretagogue may be required. Serious hypersensitivity reactions have been reported in patients treated with TRADJENTA including anaphylaxis, angioedema, and exfoliati Continue reading >>

Dpp-4 Inhibitors Januvia, Onglyza, Trajenta, Combiglyze, Janumet, And Jentadueto

Dpp-4 Inhibitors Januvia, Onglyza, Trajenta, Combiglyze, Janumet, And Jentadueto

The image I've chosen for this page is the Roman god, Janus, whose prime characteristic of facing in two directions seems very appropriate for the similarly named drug Januvia, which can be extremely effective and extremely dangerous. Januvia was the first of a family of diabetes drugs that works by increasing the levels of GLP-1 in the bloodstream. Newer drugs in this family include Onglyza and Trajenta, as well as combination drugs which mix the incretin drug in the same pill as metformin. These drugs are Janumet, Kombiglyze, and Jentadueto. GLP-1 is an incretin hormone that stimulates insulin secretion. Another kind of incretin drug, which includes Byetta and Victoza are artificially synthesized molecules that behave just like GLP-1 in the body but last longer. The DPP-4 inhibitors are quite different. They are pills that cause the GLP-1 your body secretes on its own to rise to a higher than normal level by inhibiting the action of DPP-4. DPP-4 is an enzyme (a.k.a. protease) which when it is left to its own devices, chops up GLP-1 and another hormone, GIP. When DPP-4 is inhibited, GLP-1 does not get chopped up and remains active in the body. When GLP-1 is active, it stimulates insulin secretion when blood sugars rise. The Fatal Flaw with These Drugs: They Cause Abnormal Cell Growth and Pre-cancerous Tumors in the Pancreas For several years the FDA has been getting reports that drugs in both families of incretin drugs were causing pancreatitis, a painful inflammation of the pancreas that can destroy large portions of it and lead to full-fledged Type 1 diabetes or even death. They recently decided to study the issue, though, in typical FDA fashion they merely asked for more research without warning doctors to take patients off these dangerous drugs. A study run by a bi Continue reading >>

Testing The Therapeutic Equivalence Of Alogliptin, Linagliptin, Saxagliptin, Sitagliptin Or Vildagliptin As Monotherapy Or In Combination With Metformin In Patients With Type 2 Diabetes.

Testing The Therapeutic Equivalence Of Alogliptin, Linagliptin, Saxagliptin, Sitagliptin Or Vildagliptin As Monotherapy Or In Combination With Metformin In Patients With Type 2 Diabetes.

HTA Unit, ESTAV Toscana Centro, Regional Health Service, 50100, Florence, Italy, [email protected] In studying the therapeutic evidence of innovative drug treatments, increasing attention is being devoted to differentiating between results that indicate no significant differences among the treatments under examination ("no proof of difference") and results that demonstrate the therapeutic equivalence among the treatments ("proof of no difference"). Our analysis was aimed at evaluating the degree of therapeutic equivalence for dipeptidylpeptidase-4 (DPP-4) inhibitors given in type 2 diabetes as monotherapy or in combination with metformin. Equivalence was determined by developing a standard Forest plot that incorporated the information on margins previously reported in randomized trials on these agents. The end point was HbA1c change from baseline; the equivalence margin was set at 0.25% change in HbA1c. The clinical material was obtained from a systematic review on this topic. Given as monotherapy, linagliptin, sitagliptin, and vildagliptin (but not saxagliptin) met the equivalence criterion when compared with one another. Given in combination with metformin, linagliptin, saxagliptin, sitagliptin, and vildagliptin showed an equivalent effect whereas alogliptin did not satisfy the equivalence criterion. Considering the most recent therapeutic guidelines, our results are of interest particularly as regards the information on DPP-4 inhibitors in combination with metformin. Four of the five DPP-4 inhibitors under examination clearly showed to have the same effectiveness; the fifth agent-alogliptin-failed to meet the equivalence criterion, but only because its superiority could not be excluded. Images from this publication. See all images (1) Free text Forest plo Continue reading >>

Bem | Tradjenta Januvia Conversion 176573

Bem | Tradjenta Januvia Conversion 176573

Home Forums Program Pengenalan Kampus Tradjenta Januvia Conversion 176573 This topic contains 0 replies, has 1 voice, and was last updated by This amazing site, which includes experienced business for 9 years, is one of the leading pharmacies on the Internet. They are available 24 hours each day, 7 days per week, through email, online chat or by mobile. Everything we do at this amazing site is 100% legal. 24/7 Customer Support. Free Consultation! Compare Januvia vs Tradjenta Comprehensive Analysis by Compare Januvia vs. Tradjenta, which is better for uses like: Type 2 Diabetes. Compare head-to-head ratings, side effects, warnings, dosages, interactions and patient DPP-4 INHIBITORS Dipeptidyl peptidase-4 inhibitor DPP-4 INHIBITORS, Dipeptidyl peptidase-4 inhibitor Gliptins, Linagliptin , Tradjenta,Saxagliptin , Onglyza, Sitagliptin , Januvia, KOMBIGLYZE XR Glucose Conversion Guide Tradjenta (linagliptin)Reference the glucose conversion guide for more information on how to translate A1C levels into estimated average glucose levels (eAG conversion).www.pbm.va.govSaxagliptin (Onglyza) Guidance for Conversion. February 2014. VA Pharmacy Benefits Management Services, the Medical Advisory Panel and the VISN Pharmacist ExecutivesJanuvia cheap viagra href=viagra online vs Tradjenta comparedmeds.comJanuvia vs Tradjenta. Januvia: Tradjenta: Sitagliptin is used with a proper diet and exercise program and possibly with other medications to control high blood sugar.Tradjenta Dosage Guide Drugs.comDetailed dosage guidelines and administration information for Tradjenta (linagliptin). Includes dose adjustments, warnings and precautions.Januvia and Tradjenta Battle For DPP-4 SupremacyJanuvia is facing increased competition in a market space that seems to be getting evermore crowded. The Continue reading >>

Compare Januvia Vs Tradjenta - Comprehensive Analysis By Treato

Compare Januvia Vs Tradjenta - Comprehensive Analysis By Treato

Diabetes Cancer COPD Alzheimer's Hepatitis C Treato does not review third-party posts for accuracy of any kind, including for medical diagnosis or treatments, or events in general. Treato does not provide medical advice, diagnosis or treatment. Usage of the website does not substitute professional medical advice. The side effects featured here are based on those most frequently appearing in user posts on the Internet. The manufacturer's product labeling should always be consulted for a list of side effects most frequently appearing in patients during clinical studies. Talk to your doctor about which medications may be most appropriate for you. The information reflected here is dependent upon the correct functioning of our algorithm. From time-to-time, our system might experience bugs or glitches that affect the accuracy or correct application of mathematical algorithms. We will do our best to update the site if we are made aware of any malfunctioning or misapplication of these algorithms. We cannot guarantee results and occasional interruptions in updating may occur. Please continue to check the site for updated information. Continue reading >>

Dpp-4 Inhibitors (gliptins)

Dpp-4 Inhibitors (gliptins)

DPP-4 inhibitors are prescribed for type 2 diabetes patients who do not respond well to metformin and sulphonylureas Dipeptidyl peptidase-4 (DPP-4) inhibitors are a relatively new class of oral diabetes drugs. Also known as gliptins, they are usually prescribed for people with type 2 diabetes who have not responded well to drugs such as metformin and sulphonylureas. DPP-4 inhibitors may help with weight loss as well as decreasing blood glucose levels, but have been linked with higher rates of pancreatitis. Tradjenta (Linagliptin) approved for use in the USA They work by blocking the action of DPP-4, an enzyme which destroys a group of gastrointestinal hormones called incretins. Incretins help stimulate the production of insulin when it is needed (e.g. after eating) and reduce the production of glucagon by the liver when it is not needed (e.g. during digestion). They also slow down digestion and decrease appetite. So by protecting incretins from damage, DPP-4 inhibitors help regulate blood glucose levels. DPP-4 inhibitors may be used as a second or third line medication for people with type 2 diabetes after prescribing metformin and sulphonylureas , and as an alternative to thiazolidinedione medication. Gliptins are effective in lowering blood glucose levels and, because they can help reduce appetite, may be beneficial for people needing to lose weight. Adverse effects of DPP-4 inhibitors include: gastrointestinal problems including nausea, diarrhoea and stomach pain flu-like symptoms headache, runny nose, sore throat skin reactions painful skin followed by a red or purple rash If you have a reaction which causes difficulty breathing or a severe skin reaction, call for medical help. DPP-4 inhibitors have been linked with an increased risk of pancreatitis . If you experi Continue reading >>

Januvia Tradjenta Conversion - Dexmedica

Januvia Tradjenta Conversion - Dexmedica

FDA warns of severe joint pain risk with DPP-4 diabetes drugs A class of diabetes drugs that include Merck & Co Incs Januvia has been linked with severe joint pain, the U.S. Food and Drug Administration said on Friday.,The FDA said it had identified 33 cases of severe joint pain in patients taking a class of drugs known as DPP-4 inhibitors between Oct. 16, 2006, when the first one was approved, through Dec. 31, 2013.,The most frequent number of cases, 28, occurred with Januvia, known generically as sitagliptin. Five cases were reported with AstraZeneca Plcs Onglyza... FDA approves first diabetes-cholesterol combo pill (AP) -- The first combination pill for the millions of people with the dangerous combination of diabetes and high cholesterol won U.S. approval Friday, offering convenience - and savings - to patients taking multiple pills.Juvisync, a probable blockbuster developed by Merck & Co. Inc., will be launched in a few weeks. It combines Merck's Type 2 diabetes pill Januvia with Zocor, a former Merck blockbuster in the widely used class of cholesterol drugs called statins.The combination pill will sell for the... FDA Okays New Incretin Therapy for Diabetes The FDA has approved another incretin therapy, linagliptin (Tradjenta), for treatment of type 2 diabetes, the agency announced.The dipeptidyl peptidase-4 (DPP-4) inhibitor is indicated in conjunction with diet and exercise to control glycated hemoglobin levels in adults with the disease, the FDA said.Linagliptin has been studied as monotherapy or as an add-on to metformin, glimepiride, or pioglitazone in a series of eight clinical trials totaling about 3,800 patients -- although it has not yet been assessed... Saxagliptin, Alogliptin Linked to Heart Failure, FDA Warns Diabetes drugs containing saxagliptin (Ongl Continue reading >>

Discovery And Development Of Dipeptidyl Peptidase-4 Inhibitors

Discovery And Development Of Dipeptidyl Peptidase-4 Inhibitors

Discovery and development of dipeptidyl peptidase-4 inhibitors Dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors) are enzyme inhibitors that inhibit the enzyme dipeptidyl peptidase-4 (DPP-4). They are used in the treatment of type 2 diabetes . Inhibition of the DPP-4 enzyme prolongs and enhances the activity of incretins that play an important role in insulin secretion and blood glucose control regulation. [1] Type 2 diabetes is a chronic metabolic disease that results from inability of the -cells in the pancreas to secrete sufficient amounts of insulin to meet the body's needs. Insulin resistance and increased hepatic glucose production can also play a role by increasing the body's demand for insulin. Current treatments , other than insulin supplementation, are sometimes not sufficient to achieve control and may cause undesirable side effects , such as weight gain and hypoglycemia . In recent years, new drugs have been developed, based on continuing research into the mechanism of insulin production and regulation of the metabolism of sugar in the body. The enzyme DPP-4 has been found to play a significant role. [2] Since its discovery in 1967, serine protease DPP-4 has been a popular subject of research. [2] Inhibitors of DPP-4 have long been sought as tools to elucidate the functional significance of the enzyme . The first inhibitors were characterized in the late 1980s and 1990s. Each inhibitor was important to establish an early structure activity relationship (SAR) for subsequent investigation. It should be noted that the inhibitors fall into two main classes, those that interact covalently with DPP-4 and those that do not. [3] DPP-4 is a dipeptidase that selectively binds substrates that contain proline at the P1-position, thus many DPP-4 inhibitors have 5-memb Continue reading >>

Compare Tradjenta Vs Januvia - Iodine.com

Compare Tradjenta Vs Januvia - Iodine.com

Head-to-head comparisons of medication uses, side effects, ratings, and more. Tradjenta (linagliptin) is good add-on medicine for controlling your blood sugar, but may cause body aches. Januvia (sitagliptin) is a good add-on treatment if your blood sugars are not controlled and you don't want to use an injectable medicine. 3.2/ 5 average rating with 143 reviewsforJanuvia Good add-on medicine if your blood sugars are still not controlled Good option if you have bad liver or kidney function. Does not cause hypoglycemia (low blood sugar) when taken by itself. Januvia (sitagliptin) is not linked to worsening heart failure like other medicines in its class. Uses the hormones naturally produced by your body to affect how sugar is processed. It is less likely to cause weight gain and low blood sugar compared to other diabetes medicines. Not first-choice anti-diabetes medicine because it doesn't lower blood sugar levels as much as others. Available as brand only and may be expensive Lowers A1c (average blood sugar over time) by less than 1%. Some people might get frequent cold-like symptoms. Rare but serious side effects include pancreatitis and severe joint pain. Continue reading >>

Dpp-iv Inhibitors

Dpp-iv Inhibitors

Inhibits the degradation of incretins such as GLP-1 by inhibiting the enzyme dipeptidyl peptidase IV (DPP-IV). The incretin effect is prolonged, enhancing glycemic control through various mechanisms, primarily by stimulating insulin synthesis and secretion in a glucose-dependant manner and by reducing glucagon secretion. brand name preparation manufacturer route form dosage^ cost* Januvia sitagliptin phosphate Merck oral tablet 25 mg $885 for 90 tabs oral tablet 50 mg $885 for 90 tabs oral tablet 100 mg $295 for 30 tabs Onglyza saxagliptin Bristol-Myers Squibb oral tablet 2.5 mg $295 for 30 tabs oral tablet 5 mg $885 for 90 tabs Tradjenta linagliptin Eli Lilly oral tablet 5 mg $870 for 90 tabs Janumet sitagliptin phosphate + metformin hydrochloride Merck Sharp & Dohme Corp. oral tablet 50/500 mg $885 for 180 tabs oral tablet 50/1000 mg $885 for 180 tabs Nesina alogliptin Takeda oral tablet 6.25 mg $374 for 30 tabs oral tablet 12.5 mg $374 for 30 tabs oral tablet 25 mg $374 for 30 tabs **Patient Assistant Programs: ** Information gathered by Heather Tran and Gladimir Elysee *Prices represent cost per unit specified, are representative of "Average Wholesale Price" (AWP). ^Dosage is indicated in mg unless otherwise noted. Continue reading >>

Dpp-4 Inhibitors Charts & Dosing Information For Special Populations

Dpp-4 Inhibitors Charts & Dosing Information For Special Populations

Forms, dosages and dosing considerations for pregnancy, breastfeeding, hepatic and renal. brand name preparation manufacturer route form dosage^ Januvia sitagliptin phosphate (Plus Metformin) Merck oral tablet 25 mg oral tablet 50 mg oral tablet 100 mg Onglyza Saxagliptin (Plus with metformin) Bristol-Myers Squibb oral tablet 2.5 mgD oral tablet 5 mg Tradjenta Linagliptin (Plus with metformin) Eli Lilly oral tablet 5 mg Janumet sitagliptin phosphate + metformin hydrochloride Merck Sharp & Dohme Corp. oral tablet 50/500 mg oral tablet 50/1000 mg Nesina alogliptin Takeda oral tablet 6.25 mg oral tablet 12.5 mg oral tablet 25 mg Dosing (Oral Tablet) Sitagliptin: recommended dose is 25-100 mg once a day. Can be taken with or without food. Saxagliptin: recommended dose is 2.5 or 5 mg once a day. Can be taken with or without food. Linagliptin: recommended dose is 5 mg once a day. Can be taken with or without food. Sitagliptin + metformin: co-formulated as Janumet 50/500 mg twice a day, with meals. Can increase to 50/1000 mg twice a day, with meals (maximum dose). Saxagliptin + metformin XR: co-formulated as Kombiglyze. 2.5/1000 mg, 5/1000 mg, or 5/2000 mg once daily with evening meal. Alogliptin: recommended dose is 25 mg once daily. DPP-4 inhibitors are FDA approved for use as monotherapy in type 2 diabetes (T2DM). DPP-4 inhibitors can also be added to patients already on metformin, sulfonylureas, thiazolidinediones, or insulin. If adding DPP-4 inhibitors to sulfonylurea/insulin therapy, consider decreasing the sulfonylurea/insulin dose, to reduce hypoglycemia risk. DOSING IN SPECIAL POPULATIONS – RENAL Sitagliptin GFR ≥ 50 mL/min, no dosage adjustment needed GFR 30-50 mL/min, do not exceed 50 mg daily GFR < 30 mL/min, do not exceed 25 mg daily For patients on hemodialys Continue reading >>

Oral Diabetes Medications

Oral Diabetes Medications

Oral diabetes medicines (taken by mouth) help control blood sugar (glucose) levels in people whose bodies still produce some insulin, such as some people with type 2 diabetes. These medicines are prescribed along with regular exercise and changes in the diet. Many oral diabetes medications may be used in combination with each other or with insulin to achieve the best blood glucose control. This guide provides general information about the different oral medicines for diabetes. It will help you learn more about your medication. Always take your medicine exactly as your doctor prescribes it. Discuss your specific questions and concerns with your health care provider. Sulfonylureas Glipizide (Glucotrol®, Glucotrol XL®,), Glimepride (Amaryl®), Glyburide (DiaBeta®, Glynase PresTab®, Micronase®) These medications lower blood glucose by causing the pancreas to release more insulin. Biguanides Metformin (Glucophage®, Glucophage XR®, Glumetza®, Fortamet®, Riomet®) These medications reduce how much glucose the liver produces. It also improves how insulin works in the body, and slows down the conversion of carbohydrates into sugar. Thiazolidinediones Pioglitozone (Actos®), rosiglitozone (Avandia®) These medications improve the way insulin works in the body by allowing more glucose to enter into muscles, fat, and the liver. Alpha-glucosidase inhibitors Acarbose (Precose®,) miglitol (Glyset®) These medications lower blood glucose by delaying the breakdown of carbohydrates and reducing glucose absorption in the small intestine. They also block certain enzymes in order to slow down the digestion of some starches. Meglitinide Repaglinide (Prandin®), nateglinide (Starlix®) These medications lower blood glucose by getting the pancreas to release more insulin. DPP-4 inhib Continue reading >>

More in diabetes